Scandiatransplant Report 2009

doi:10.1016/j.transproceed.2010.09.111

Transplantation Proceedings

Volume 42, Issue 10, December 2010, Pages 4429-4431

https://doi.org/10.1016/j.transproceed.2010.09.111 Get rights and content

Abstract

Scandiatransplant is the Nordic organ exchange organization that has existed for 41 years by a close collaboration between transplant centers. It has been valuable to ensure the optimal usage of available organs for transplantation. Analyzing the database for the past 15 years (1995–2009) revealed that the fraction of organ donors in the age category 60 to 90 years has increased considerably. The number of retrieved organs from deceased donors increased for kidney, liver, and lungs but only slightly for hearts. In the last time period, the mean number of organs retrieved per deceased donor counting only those having a recipient increased to 3.7 for younger donors and to 2.6 from the older group. In 2009, the STAMP (Scandiatransplant acceptable mismatch program) was launched to help highly immunized kidney patients. In 2009, kidney transplantations exhibited for Norway, 60 per million people (pmp); more than 40 pmp for Sweden and for Denmark; approximately 35 pmp for Finland; and more than 20 pmp for the living donor kidney transplantations in Iceland. The best year ever within Scandiatransplant with respect to total number of organ transplantations from deceased and living donors was 2009.

Section snippets

Acknowledgments

Transplant coordinators, nurses, laboratory technicians, and doctors are cordially thanked for their thorough maintenance of the Scandiatransplant waiting list and transplantation database. The work of the staff of Scandiatransplant (Susanne Sønder, Christian Mondrup, Bo Hedemark Pedersen, Jörn Hajek, and especially Frank Pedersen and Ilse Duus Weinreich) is gratefully acknowledged.

Reference (1)

Cited by (6)

Rescue liver transplantation after post-hepatectomy acute liver failure: A systematic review and pooled analysis
2023, Transplantation Reviews
Post-hepatectomy liver failure is a severe complication after major liver resection and is associated with a high mortality rate. Nevertheless, there is no effective treatment for severe liver failure. In such a setting, rescue liver transplantation (LT) is used only in extraordinary cases with unclear results. This systematic review aims to define indication of LT in post-hepatectomy liver failure and post-LT outcomes, in terms of patient and disease-free survivals, to assess the procedure's feasibility and effectiveness.
A systematic review of all English language full-text articles published until September 2022 was conducted. Inclusion criteria were articles describing patients undergoing LT for post-hepatectomy liver failure after liver resection, which specified at least one outcome of interest regarding patient/graft survival, postoperative complications, tumour recurrence and cause of death. A pseudo-individual participant data meta-analysis was performed to analyse data. Study quality was assessed with MINORS system. PROSPERO CRD42022349358.
Postoperative complication rate was 53.6%. All patients transplanted for benign indications survived. For malignant tumours, 1-, 3- and 5-year overall survival was 94.7%, 82.1% and 74.6%, respectively. The causes of death were tumour recurrence in 83.3% of cases and infection-related in 16.7% of LT recipients. At Cox regression, being transplanted for unconventional malignant indications (colorectal liver metastasis, cholangiocarcinoma) was a risk factor for death HR = 8.93 (95%CI = 1.04–76.63; P-value = 0.046). Disease-free survival differs according to different malignant tumours (P-value = 0.045).
Post-hepatectomy liver failure is an emergent indication for rescue LT, but it is not universally accepted. In selected patients, LT can be a life-saving procedure with low short-term risks. However, special attention must be given to long-term oncological prognosis before proceeding with rescue LT in an urgent setting, considering the severity of liver malignancy, organ scarcity, the country's organ allocation policies and the resource of living-related donation.
Treating diabetes with islet transplantation: Lessons learnt from the nordic network for clinical islet transplantation
2019, Transplantation, Bioengineering, and Regeneration of the Endocrine Pancreas: Volume 1
In this chapter we will present the Nordic experiences with clinical islet transplantation after starting The Nordic Network for Clinical Islet Transplantation in 2000. In addition, we will also present a local multidisciplinary effort organized as a Center of Excellence in Type 1 Diabetes. Over time islet transplantation has shifted from having been clinical research to becoming an established clinical activity. In the Nordic countries it is now considered as innovative rather than an experimental therapy. Islet transplantation is underused, technically complex, highly specialized, and with a need for multidisciplinary expertise, which is why it for the foreseeable future will continue to be centralized to a few centers to ensure high quality and continued development. The aim of our different networks, both local and regional, is to offer the best treatment for those patients for whom conventional treatment is inadequate and take advantage of the expertise distributed in several different disciplines.
Current status of the scandiatransplant acceptable mismatch program
2013, Transplantation Proceedings
This article describes the Scandiatransplant Acceptable Mismatch Program (STAMP), which was set into action in 2009. The aim of STAMP is to define human leukocyte antigens (HLA) toward which the potential kidney recipient has not developed antibodies, as “acceptable mismatches” in the Scandiatransplant database. In many cases this may improve the probability for a highly immunized recipient to receive a suitable kidney graft from a deceased donor. Using data extracted from the Scandiatransplant database on the outcomes of the program after the first 3 years, 31/115 recipients included in the program have undergone transplantation. From 2008 to 2011 the mean waiting time for highly immunized patients has decreased from 42 to 37 months. Continuous evaluation and follow-up of the program is essential to improve the procedures and outcomes. Calculation of transplantability based on a given set of acceptable mismatches was added to the program in 2011, based on the historical deceased donor pool providing the possibility of a specific patient to receive a kidney through STAMP. It is still a challenge for the tissue typing laboratories to determine which detected HLA antibodies are clinical relevant. We concluded that STAMP has had the intended effects, however adjustments and improvements is an ongoing process. As an improvment of the program HLA-C was added to the STAMP search algorithm in September 2012.
Altruism and Religion: A New Paradigm for Organ Donation
2018, Journal of Religion and Health
HLA Associations and Risk of Posttransplant Lymphoproliferative Disorder in a Danish Population-Based Cohort
2015, Transplantation Direct
Liver transplantation in the Nordic countries-An intention to treat and post-transplant analysis from the Nordic Liver Transplant Registry 1982-2013
2015, Scandinavian Journal of Gastroenterology

View full text

Donation and allocationScandiatransplant Report 2009

Abstract

Section snippets

Acknowledgments

Donation and allocation
Scandiatransplant Report 2009